中文:PNH是一种罕见的血液病,其特征是睡眠时血红蛋白尿的发作。 英文:PNH is a rare blood disorder characterized by the occurrence of hemoglobinuria during sleep. 中文:研究表明,PNH可能与免疫系统异常有关。 英文:Research indicates that PNH may be related to immune syst...
But it’s important to get out there and find others who have PNH. Research shows that people who live with a rare disease, and their caretakers, are 3 more times more likely to report that they have feelings of unhappiness and depression. Social support can help. Here’s why it’s imp...
Introduction: Paroxysmal nocturnal hemoglobinuria (PNH) is an acquired, life-threatening blood disease. While PNH is known to be a rare disease, the incide... JJ Jalbert,U Chaudhari,H Zhang,... - 《Blood》 被引量: 0发表: 2019年 The population dynamics of cancer: a Darwinian perspective....
Paroxysmal nocturnal haemoglobinuria is an ultra-rare disease and potentially life-threatening disease. Learn more about the causes, symptoms, and unmet needs.
Daily blood pressure profile and blood–brain barrier permeability in patients with cerebral small vessel disease Article Open access 11 May 2022 Introduction Paroxysmal nocturnal hemoglobinuria (PNH) is a rare acquired stem cell disorder (incidence of 2–6 per million) characterized by hemolytic anemi...
The overall and relative 5-year survival rates were 72% and 82.7%, respectively.#This study showed that classical haemolytic PNH is a rare disease and represents only a small proportion overall of patients with detectable PNH cells, the majority of which have aplastic anaemia.doi:10.1111/ejh....
Rare BloodHealth Care DeliveryProviders September 1st 2024 Advancing Health Equity in Cardiovascular Care: A New Frontier Maggie L. Shaw David Thompson, PhD, Queen’s University Belfast, expands on previous research he conducted that calls for cardiovascular health care providers to actively address car...
The introduction of successful isolation procedures resulted in rapidly progressive research efforts, but the concept of the functional role of this cell type made a full about turn between the 1970s and 1980s. In the 1970s, the role......
Iptacopan met the primary endpoint in the Phase III trial as a treatment for the rare complement-mediated kidney disease C3 glomerulopathy.
About BioCryst Pharmaceuticals BioCryst Pharmaceuticals discovers novel, oral, small-molecule medicines that treat rare diseases in which significant unmet medical needs exist and an enzyme plays a key role in the biological pathway of the disease. BioCryst has several ongoing development programs ...